Switching to doravirine in cART experienced patients: An effective and highly tolerated option with substantial cost savings. Lanting VR, Oosterhof P, Moha DA, van Heerde R, et al. J Acquir Immune Defic Syndr 2023 Nov 10. doi: 10.1097/QAI.0000000000003337.

Read + Share

Amedeo Smart

Independent Medical Education

Lanting VR, Oosterhof P, Moha DA, van Heerde R, et al. Switching to doravirine in cART experienced patients: An effective and highly tolerated option with substantial cost savings. J Acquir Immune Defic Syndr 2023 Nov 10. doi: 10.1097/QAI.0000000000003337.
PMID: 37963350